Evaluation of NEVELIA® in Terms of Safety and Efficacy for Third-degree Burns Treatment or Reconstructive Surgery (NEVAL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02089490|
Recruitment Status : Unknown
Verified March 2014 by Symatese.
Recruitment status was: Not yet recruiting
First Posted : March 17, 2014
Last Update Posted : March 17, 2014
The dermal substitute NEVELIA® has received CE marking in July 9, 2013. Its use in the NEVAL protocol will be in accordance with its leaflet, i.e. for the treatment of burns or in case of reconstructive plastic surgery.
The matric implantation will be followed by autologous skin grafting when the neodermis formation will be observed.
|Condition or disease||Intervention/treatment||Phase|
|Third-degree Burns Reconstructive Surgery||Device: NEVELIA® implantation||Not Applicable|
The NEVAL protocol is a descriptive study conducted in order to confirm the clinical evidence of safety and performance of NEVELIA®, as described in the literature on equivalent products.
This dermal substitute consists of an inner biodegradable dermal substitute made of bovine collagen (collagen of type I), covered with an outer silicone membrane. Its porosity and the speed of degradation allow the act of recolonization by the fibroblasts and initiation of the vascularization process within 3 weeks. The application procedure requires removement of the silicone layer and wound covering with an ultra-thin epidermal graft, possibly meshed. This surgical procedure is well-known and permits an ultra-thin epidermal graft.
All the patients will be treated with NEVELIA®, prior to autologous skin grafting within 3 weeks after its application. Then, three follow-up visits will be planned: post operatively, at 6 and 12 months.
The objectives are:
- Primary objective: To assess the type and frequency of complications
- To assess the take rate of NEVELIA®
- To assess the take rate of skin graft
- To assess the satisfaction rate of physician and patient,
- To assess the quality of the healed skin,
- To assess the rate of re-operation at 12 months.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Prospective Follow-up Study for the Evaluation of the Safety and Efficacy of the Dermal Substitute NEVELIA® in the Treatment of Third-degree Burns and Reconstructive Surgery|
|Study Start Date :||April 2014|
|Estimated Primary Completion Date :||January 2016|
|Estimated Study Completion Date :||April 2016|
NEVELIA® implantation according to the intended use in the leaflet, prior to autologous skin grafting planned 3 weeks after its application.
Device: NEVELIA® implantation
Skin substitute implantation followed by ultra-thin epidermal graft
- Assessment of the type and frequency of complications related to NEVELIA® [ Time Frame: Up to 12 months ]
- Take rate of NEVELIA® [ Time Frame: At Day 21 ]
- Take rate of skin graft [ Time Frame: At Day 28, 6 and 12 months ]
- Satisfaction rate of physician and patient [ Time Frame: At 6 and 12 months ]
- Quality of healed skin [ Time Frame: At 6 and 12 months ]Vancouver score
- Re-operation rate [ Time Frame: At 12 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02089490
|Contact: Sophie AMAT-JARLIERemail@example.com|
|Contact: Chantal BELINfirstname.lastname@example.org|
|Centre François Xavier Michelet - CHU de Bordeaux||Not yet recruiting|
|Bordeaux, France, 33076|
|Contact: Vincent Casoli, MD PhD +33556795591 email@example.com|
|Principal Investigator: Vincent Casoli, MD PhD|
|Principal Investigator:||Vincent Casoli, MD PhD||Centre François Xavier Michelet - CHU de Bordeaux, FRANCE|